for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bio-Path Holdings Inc

BPTH.OQ

Latest Trade

12.78USD

Change

1.79(+16.29%)

Volume

63,167

Today's Range

10.98

 - 

13.33

52 Week Range

1.63

 - 

73.52

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
10.99
Open
10.98
Volume
63,167
3M AVG Volume
1.41
Today's High
13.33
Today's Low
10.98
52 Week High
73.52
52 Week Low
1.63
Shares Out (MIL)
2.88
Market Cap (MIL)
31.69
Forward P/E
-3.43
Dividend (Yield %)
--

Latest Developments

More

Bio-Path Updates Intellectual Property Portfolio With Addition Of Recently Issued Second Platform Technology Patent

Bio-Path Holdings Reports Second Quarter 2019 Financial Results

Bio Path Holdings Files For Stock Shelf Of Up To $125 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bio-Path Holdings Inc

Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification. Its lead drug candidate, Liposomal Grb2 (BP1001), targets the protein Growth factor receptor-bound protein 2 (Grb2). Its other liposome delivered antisense drug candidate, Liposomal Bcl2 (BP1002), targets the protein B-cell lymphoma 2 (Bcl2). BP1001 is in Phase II clinical trials for acute myeloid leukemia, and for blast phase and accelerated phase chronic myelogenous leukemia. BP1002 is intended to target the lymphoma and certain solid tumor markets. BP1001 is also in preclinical studies for solid tumors, including triple negative breast cancer and inflammatory breast cancer.

Industry

Biotechnology & Drugs

Contact Info

4710 Bellaire Blvd Ste 210

+1.832.7421357

http://www.biopathholdings.com/

Executive Leadership

Peter Henry Nielsen

Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer

Douglas P. Morris

Secretary, Director

Paul D. Aubert

Independent Director

Heath W. Cleaver

Independent Director

Martina Molsbergen

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2019(E)

0.0K
EPS (USD)

2016

-18.000

2019(E)

-3.200
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.74
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-77.82
Return on Equity (TTM)
-71.49

Latest News

Latest News

BRIEF-Bio-Path Holdings Reports Full Year 2017 Financial Results

* PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULTS Source text for Eikon: Further company coverage:

BRIEF-Bio Path Holdings Says Board Increased Its Size From Four Members To Five Members

* BIO PATH HOLDINGS INC SAYS ON FEB 1, 2018, BOARD OF CO, INCREASED ITS SIZE FROM FOUR MEMBERS TO FIVE MEMBERS - SEC FILING Source text: [http://bit.ly/2GQ9Xup] Further company coverage:

BRIEF-Bio Path Holdings Provides Clinical Update And 2018 Business Outlook

* BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2018 BUSINESS OUTLOOK

BRIEF-Bio-Path Holdings Q3 loss per share $0.02

* Bio-Path Holdings reports third quarter 2017 financial results

BRIEF-Bio-Path Holdings announces $4 mln registered direct offering

* Bio-Path Holdings, Inc. Announces $4 million registered direct offering

BRIEF-Bio Path Holdings receives notice of allowance for key U.S. composition of matter patent

* Bio Path Holdings - U.S. PTO has issued notice of allowance for claims related to co's liposomal delivery and antisense technology, dnabilize Source text for Eikon: Further company coverage:

BRIEF-Bio-Path Holdings appoints Mark Colonnese to its board

* Bio-Path Holdings appoints Mark Colonnese to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Bio Path Holdings reports Q1 loss per share of $0.01

* Bio-Path Holdings reports first quarter 2017 financial results

BRIEF-Bio-Path holdings presents results showing potential of BP1002

* Bio-Path holdings presents results showing potential of BP1002 as treatment for aggressive non-hodgkin’s lymphoma

BRIEF-Bio-Path Holdings reports Q3 financial results

* Bio-Path Holdings reports third quarter 2016 financial results

BRIEF-Bio-Path's BP1001 gets orphan drug designation in EU for treatment of acute myeloid leukemia

* Bio-Path announces orphan drug designation in the european union for bp1001 for the treatment of acute myeloid leukemia Source text for Eikon: Further company coverage:

BRIEF-Bio-Path Holdings updates on acute myeloid leukemia trial

* Bio-Path holdings announces first patient dosed in phase 2 trial evaluating bp1001 in acute myeloid leukemia Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up